New insider activity at Eli Lilly & Co ( (LLY) ) has taken place on February 15, 2025.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Lilly Endowment Inc, a major shareholder of Eli Lilly & Co, has recently sold 35,446 shares of the company’s stock. This transaction amounts to a substantial $31,175,217.
Recent Updates on LLY stock
Eli Lilly & Co. recently announced a global licensing agreement with OliX Pharmaceuticals to develop and commercialize OLX75016, targeting metabolic-associated steatohepatitis and other cardiometabolic conditions. The company also reported strong Q4 2024 earnings, with a significant 45% revenue increase, largely driven by the success of new products like Mounjaro and Zepbound. BofA raised Eli Lilly’s price target due to “good” Q4 results and promising FY25 EPS guidance, with revenue and EPS forecasts reflecting positive growth expectations. Eli Lilly’s strategic growth initiatives, including new product approvals and collaborations, have been highlighted as key drivers of the company’s robust pipeline. However, challenges such as pricing pressures, a decline in Trulicity revenue, and supply constraints in certain regions were noted. Despite these challenges, the overall outlook remains positive, with projected revenue growth and continued product innovation.
More about Eli Lilly & Co
YTD Price Performance: 12.05%
Average Trading Volume: 3,840,258
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $827.7B